Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Colin Baigent, Jonathan Emberson, Richard Haynes, et al.
The Lancet (2022) Vol. 400, Iss. 10365, pp. 1788-1801
Open Access | Times Cited: 611

Showing 1-25 of 611 citing articles:

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
Paul E. Stevens, Sofia B. Ahmed, Juan Jesús Carrero, et al.
Kidney International (2024) Vol. 105, Iss. 4, pp. S117-S314
Open Access | Times Cited: 1997
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension
Giuseppe Mancia, Reinhold Kreutz, Mattias Brunström, et al.
Journal of Hypertension (2023) Vol. 41, Iss. 12, pp. 1874-2071
Open Access | Times Cited: 1600
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3627-3639
Open Access | Times Cited: 1005
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
Nikolaus Marx, Massimo Federici, Katharina Schütt, et al.
European Heart Journal (2023) Vol. 44, Iss. 39, pp. 4043-4140
Open Access | Times Cited: 708
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association
Chiadi E. Ndumele, Janani Rangaswami, Sheryl L. Chow, et al.
Circulation (2023) Vol. 148, Iss. 20, pp. 1606-1635
Open Access | Times Cited: 421
Chronic kidney disease and the global public health agenda: an international consensus
Anna Francis, Meera N. Harhay, Albert Ong, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 7, pp. 473-485
Open Access | Times Cited: 269
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association
Chiadi E. Ndumele, Ian J. Neeland, Katherine R. Tuttle, et al.
Circulation (2023) Vol. 148, Iss. 20, pp. 1636-1664
Open Access | Times Cited: 254
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 1, pp. 5-17
Open Access | Times Cited: 177
Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease
Michel Burnier, Aikaterini Damianaki
Circulation Research (2023) Vol. 132, Iss. 8, pp. 1050-1063
Closed Access | Times Cited: 149
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
Brendon L. Neuen, Hiddo J.L. Heerspink, Priya Vart, et al.
Circulation (2023) Vol. 149, Iss. 6, pp. 450-462
Open Access | Times Cited: 100
IgA nephropathy
Eleni Stamellou, Claudia Seikrit, Sydney C.W. Tang, et al.
Nature Reviews Disease Primers (2023) Vol. 9, Iss. 1
Closed Access | Times Cited: 76
SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
Khawaja M. Talha, Stefan D. Anker, Javed Butler
International Journal of Heart Failure (2023) Vol. 5, Iss. 2, pp. 82-82
Open Access | Times Cited: 74
Endothelial Cell Dysfunction and Increased Cardiovascular Risk in Patients With Chronic Kidney Disease
Constance C. F. M. J. Baaten, Sonja Vondenhoff, Heidi Noels
Circulation Research (2023) Vol. 132, Iss. 8, pp. 970-992
Open Access | Times Cited: 74
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Muhammad Usman, Tariq Jamal Siddiqi, Stefan D. Anker, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 25, pp. 2377-2387
Closed Access | Times Cited: 70
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial
Hiddo J.L. Heerspink, Arihiro Kiyosue, David C. Wheeler, et al.
The Lancet (2023) Vol. 402, Iss. 10416, pp. 2004-2017
Open Access | Times Cited: 68
Empagliflozin in Patients with Chronic Kidney Disease
Brendon L. Neuen, Robert A. Fletcher, Hiddo J.L. Heerspink
New England Journal of Medicine (2023) Vol. 388, Iss. 24, pp. 2300-2302
Open Access | Times Cited: 66
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis
Michelle N. Rheault, Charles E. Alpers, Jonathan Barratt, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 26, pp. 2436-2445
Closed Access | Times Cited: 60
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
Johannes F.E. Mann, Peter Rossing, George L. Bakris, et al.
Nature Medicine (2024) Vol. 30, Iss. 10, pp. 2849-2856
Open Access | Times Cited: 59
EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
Beatriz Fernández‐Fernández, Pantelis Sarafidis, María José Soler, et al.
Clinical Kidney Journal (2023) Vol. 16, Iss. 8, pp. 1187-1198
Open Access | Times Cited: 58
Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
Pierre Gourdy, Patrice Darmon, François Diévart, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 57
Differences in the epidemiology, management and outcomes of kidney disease in men and women
Nicholas C. Chesnaye, Juan Jesús Carrero, Manfred Hecking, et al.
Nature Reviews Nephrology (2023) Vol. 20, Iss. 1, pp. 7-20
Closed Access | Times Cited: 56
Metabolic syndrome
Ian J. Neeland, Soo Lim, André Tchernof, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 56
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy
Hong Zhang, Dana V. Rizk, Vlado Perkovic, et al.
Kidney International (2023) Vol. 105, Iss. 1, pp. 189-199
Open Access | Times Cited: 55
Trends and perspectives for improving quality of chronic kidney disease care: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Kai‐Uwe Eckardt, Cynthia Delgado, Hiddo J.L. Heerspink, et al.
Kidney International (2023) Vol. 104, Iss. 5, pp. 888-903
Open Access | Times Cited: 45
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis
Siddharth Patel, Yu Mi Kang, KyungAh Im, et al.
Circulation (2024) Vol. 149, Iss. 23, pp. 1789-1801
Open Access | Times Cited: 45
Page 1 - Next Page

Scroll to top